GDF-11 vs Rapamycin
A side-by-side research comparison of GDF-11 and Rapamycin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | GDF-11 | Rapamycin |
|---|---|---|
| Full name | Growth Differentiation Factor 11 | Rapamycin (Sirolimus) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved (off-label for longevity) |
| Mechanism | Signals through activin type II receptors and SMAD2/3 to restore stem cell function, promote neurogenesis, and improve vascular remodeling in the context of aging. | Inhibits mTOR complex 1 (mTORC1), reducing cellular growth signaling and activating autophagy - the cellular recycling process. Mimics caloric restriction at the molecular level. |
| Molecular weight | 12,500 Da | 914.17 Da |
| Half-life | 6-8 hours | ~62 hours |
| Bioavailability | Moderate (SubQ/IV) | ~14% oral |
| Typical dose | 0.1-0.5 mg/kg (research) | 3-6 mg |
| Frequency | Daily (animal studies) | Once weekly |
| Route | Subcutaneous | Oral tablet |
GDF-11 reported benefits
- Potential tissue rejuvenation
- Neurogenesis stimulation
- Cardiac hypertrophy reversal
- Muscle stem cell activation
- Vascular remodeling
Rapamycin reported benefits
- Enhanced autophagy
- Immune rejuvenation
- Anti-aging cellular effects
- Cancer risk reduction
- Improved vaccine response (elderly)
- Longevity extension
Related comparisons
Research and educational reference only. Not medical advice.